IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+20.34%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$693M
AUM Growth
+$693M
(-1.7%)
Cap. Flow
-$91.4M
Cap. Flow
% of AUM
-13.2%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
95
New
31
Increased
14
Reduced
20
Closed
26
Top Buys
| 1 |
AbbVie
ABBV
|
$26.3M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$22.2M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$22M |
| 4 |
Sanofi
SNY
|
$19.9M |
| 5 |
Teleflex
TFX
|
$17.5M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$50.1M |
| 2 |
argenx
ARGX
|
$34.4M |
| 3 |
McKesson
MCK
|
$21.7M |
| 4 |
Amgen
AMGN
|
$17.5M |
| 5 |
Cigna
CI
|
$17.2M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$30.3B
| $10.8M | 1.48% |
+350,000
| New | +$10.8M |
|
27
Universal Health Services
UHS
$11.6B
| $10.7M | 1.45% |
+70,000
| New | +$10.7M |
|
28
Krystal Biotech
KRYS
$4.35B
| $10.5M | 1.44% |
85,000
+15,000
| +21% | +$1.86M |
|
29
Penumbra
PEN
$10.5B
| $10.1M | 1.37% |
+40,000
| New | +$10.1M |
|
30
Icon
ICLR
$14B
| $9.91M | 1.35% |
+35,000
| New | +$9.91M |
|
31
Repligen
RGEN
$6.54B
| $9.89M | 1.35% |
+55,000
| New | +$9.89M |
|
32
Medtronic
MDT
$118B
| $9.89M | 1.35% |
120,000
-180,000
| -60% | -$14.8M |
|
33
Centene
CNC
$14.8B
| $9.65M | 1.31% |
+130,000
| New | +$9.65M |
|
34
Elevance Health
ELV
$72.4B
| $9.43M | 1.28% |
20,000
-5,000
| -20% | -$2.36M |
|
35
Viking Therapeutics
VKTX
$3.02B
| $9.31M | 1.27% |
500,000
-300,000
| -38% | -$5.58M |
|
36
Arcellx
ACLX
$3.95B
| $8.88M | 1.21% |
+160,000
| New | +$8.88M |
|
37
Alnylam Pharmaceuticals
ALNY
$58.6B
| $8.61M | 1.17% |
+45,000
| New | +$8.61M |
|
38
Evolent Health
EVH
$1.11B
| $8.26M | 1.12% |
+250,000
| New | +$8.26M |
|
39
Align Technology
ALGN
$9.59B
| $8.22M | 1.12% |
+30,000
| New | +$8.22M |
|
40
4D Molecular Therapeutics
FDMT
$302M
| $7.6M | 1.03% |
+375,000
| New | +$7.6M |
|
41
Elanco Animal Health
ELAN
$8.62B
| $7.45M | 1.01% |
500,000
-248,000
| -33% | -$3.7M |
|
42
Bruker
BRKR
$4.45B
| $7.35M | 1% |
+100,000
| New | +$7.35M |
|
43
Arvinas
ARVN
$580M
| $7.2M | 0.98% |
+175,000
| New | +$7.2M |
|
44
Hologic
HOLX
$14.7B
| $7.15M | 0.97% |
100,000
-25,000
| -20% | -$1.79M |
|
45
Crinetics Pharmaceuticals
CRNX
$3.26B
| $7.12M | 0.97% |
200,000
| – | – |
|
46
Illumina
ILMN
$15.2B
| $6.96M | 0.95% |
+50,000
| New | +$6.96M |
|
47
Alkermes
ALKS
$4.95B
| $6.91M | 0.94% |
249,000
-26,000
| -9% | -$721K |
|
48
SI-BONE Inc
SIBN
$700M
| $6.61M | 0.9% |
315,000
-170,000
| -35% | -$3.57M |
|
49
Relay Therapeutics
RLAY
$709M
| $6.61M | 0.9% |
600,000
-200,000
| -25% | -$2.2M |
|
|
NARI
50
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.49M | 0.88% |
100,000
-250,000
| -71% | -$16.2M |
|